The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lee, K.-H.
Right arrow Articles by Marincola, F. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lee, K.-H.
Right arrow Articles by Marincola, F. M.
The Journal of Immunology, 1999, 163: 6292-6300.
Copyright © 1999 by The American Association of Immunologists

Increased Vaccine-Specific T Cell Frequency After Peptide-Based Vaccination Correlates with Increased Susceptibility to In Vitro Stimulation But Does Not Lead to Tumor Regression

Kang-Hun Lee*, Ena Wang{dagger}, Mai-Britt Nielsen{dagger}, John Wunderlich{dagger}, Steven Migueles§, Mark Connors§, Seth M. Steinberg{ddagger}, Steven A. Rosenberg{dagger} and Francesco M. Marincola1,*,{dagger}

* Department of Transfusion Medicine, Clinical Center, {dagger} Surgery Branch, National Cancer Institute, {ddagger} Biostatistics and Data Management Section, National Cancer Institute, and § Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892

Although in vitro sensitization assays have shown increased melanoma Ag (MA)-specific CTL reactivity after vaccination with MA peptides, clinical responses have been uncommon. This paradox questions whether data obtained from the in vitro stimulation and expansion of T cells lead to an overestimation of the immune response to vaccines. Using HLA/peptide tetramer (tHLA), we enumerated MA-specific T cell precursor frequency (TCPF) directly in PBMC from 23 melanoma patients vaccinated with gp100:209–217(210M) (g209–2M) peptide. Vaccine-specific TCPF was higher in postvaccination PBMC from seven of seven patients treated with peptide alone and four of five patients treated with peptide plus IL-12 (range of postvaccination TCPF, 0.2–2.4% and 0.2–2.5%, respectively). The increased TCPF correlated with enhanced susceptibility to in vitro stimulation with the relevant epitope. Paradoxically, no increase in postvaccination TCPF was observed in most patients who had been concomitantly treated with IL-2 (1 of 11 patients; range of postvaccination TCPF, 0.02–1.0%), a combination associated with enhanced rates of tumor regression. The lack of increase in TCPF seen in these patients corresponded to inability to elicit expansion of vaccine-specific T cells in culture. This study shows that a peptide-based vaccine can effectively generate a quantifiable T cell-specific immune response in the PBMC of cancer patients, though such a response does not associate with a clinically evident regression of metastatic melanoma.




This article has been cited by other articles:


Home page
 Cancer Res.Home page
C. J. Wheeler, K. L. Black, G. Liu, M. Mazer, X.-x. Zhang, S. Pepkowitz, D. Goldfinger, H. Ng, D. Irvin, and J. S. Yu
Vaccination Elicits Correlated Immune and Clinical Responses in Glioblastoma Multiforme Patients
Cancer Res., July 15, 2008; 68(14): 5955 - 5964.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Worschech, M. Kmieciak, K. L. Knutson, H. D. Bear, A. A. Szalay, E. Wang, F. M. Marincola, and M. H. Manjili
Signatures Associated with Rejection or Recurrence in HER-2/neu-Positive Mammary Tumors
Cancer Res., April 1, 2008; 68(7): 2436 - 2446.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
Y. Hou, B. Kavanagh, and L. Fong
Distinct CD8+ T Cell Repertoires Primed with Agonist and Native Peptides Derived from a Tumor-Associated Antigen
J. Immunol., February 1, 2008; 180(3): 1526 - 1534.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
D. J. Powell Jr., A. Felipe-Silva, M. J. Merino, M. Ahmadzadeh, T. Allen, C. Levy, D. E. White, S. Mavroukakis, R. J. Kreitman, S. A. Rosenberg, et al.
Administration of a CD25-Directed Immunotoxin, LMB-2, to Patients with Metastatic Melanoma Induces a Selective Partial Reduction in Regulatory T Cells In Vivo
J. Immunol., October 1, 2007; 179(7): 4919 - 4928.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Perez-Diez, N. T. Joncker, K. Choi, W. F. N. Chan, C. C. Anderson, O. Lantz, and P. Matzinger
CD4 cells can be more efficient at tumor rejection than CD8 cells
Blood, June 15, 2007; 109(12): 5346 - 5354.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
K. Fischer, P. Hoffmann, S. Voelkl, N. Meidenbauer, J. Ammer, M. Edinger, E. Gottfried, S. Schwarz, G. Rothe, S. Hoves, et al.
Inhibitory effect of tumor cell-derived lactic acid on human T cells
Blood, May 1, 2007; 109(9): 3812 - 3819.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
A. Charalambous, M. Oks, G. Nchinda, S. Yamazaki, and R. M. Steinman
Dendritic Cell Targeting of Survivin Protein in a Xenogeneic Form Elicits Strong CD4+ T Cell Immunity to Mouse Survivin
J. Immunol., December 15, 2006; 177(12): 8410 - 8421.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
W. W. Overwijk, K. E. de Visser, F. H. Tirion, L. A. de Jong, T. W. H. Pols, Y. U. van der Velden, J. G. van den Boorn, A. M. Keller, W. A. Buurman, M. R. Theoret, et al.
Immunological and Antitumor Effects of IL-23 as a Cancer Vaccine Adjuvant
J. Immunol., May 1, 2006; 176(9): 5213 - 5222.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
A. B. Frey and N. Monu
Effector-phase tolerance: another mechanism of how cancer escapes antitumor immune response
J. Leukoc. Biol., April 1, 2006; 79(4): 652 - 662.
[Abstract] [Full Text] [PDF]

Home page
 Exp. Biol. Med.Home page
B. Wu, A. Ootani, R. Iwakiri, Y. Sakata, T. Fujise, S. Amemori, F. Yokoyama, S. Tsunada, S. Toda, and K. Fujimoto
T Cell Deficiency Leads to Liver Carcinogenesis in Azoxymethane-Treated Rats
Experimental Biology and Medicine, January 1, 2006; 231(1): 91 - 98.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Yang, K.-Y. Tsang, and J. Schlom
Induction of Higher-Avidity Human CTLs by Vector-Mediated Enhanced Costimulation of Antigen-Presenting Cells
Clin. Cancer Res., August 1, 2005; 11(15): 5603 - 5615.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Y. Nagata, T. Hanagiri, M. Takenoyama, T. Fukuyama, M. Mizukami, T. So, Y. Ichiki, M. Sugaya, K. Sugio, and K. Yasumoto
Identification of the HLA-Cw*0702-Restricted Tumor-Associated Antigen Recognized by a CTL Clone from a Lung Cancer Patient
Clin. Cancer Res., July 15, 2005; 11(14): 5265 - 5272.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Y. Suzuki, D. Wakita, K. Chamoto, Y. Narita, T. Tsuji, T. Takeshima, H. Gyobu, Y. Kawarada, S. Kondo, S. Akira, et al.
Liposome-Encapsulated CpG Oligodeoxynucleotides as a Potent Adjuvant for Inducing Type 1 Innate Immunity
Cancer Res., December 1, 2004; 64(23): 8754 - 8760.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
V. Monsurro, E. Wang, Y. Yamano, S. A. Migueles, M. C. Panelli, K. Smith, D. Nagorsen, M. Connors, S. Jacobson, and F. M. Marincola
Quiescent phenotype of tumor-specific CD8+ T cells following immunization
Blood, October 1, 2004; 104(7): 1970 - 1978.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. J. Wheeler, A. Das, G. Liu, J. S. Yu, and K. L. Black
Clinical Responsiveness of Glioblastoma Multiforme to Chemotherapy after Vaccination
Clin. Cancer Res., August 15, 2004; 10(16): 5316 - 5326.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
H. L. Hanson, S. S. Kang, L. A. Norian, K. Matsui, L. A. O'Mara, and P. M. Allen
CD4-Directed Peptide Vaccination Augments an Antitumor Response, but Efficacy Is Limited by the Number of CD8+ T Cell Precursors
J. Immunol., April 1, 2004; 172(7): 4215 - 4224.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. Yang and F. G. Haluska
Treatment of Melanoma with 5-Fluorouracil or Dacarbazine In Vitro Sensitizes Cells to Antigen-Specific CTL Lysis through Perforin/Granzyme- and Fas-Mediated Pathways
J. Immunol., April 1, 2004; 172(7): 4599 - 4608.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Y. Sugita, H. Wada, S. Fujita, T. Nakata, S. Sato, Y. Noguchi, A. A. Jungbluth, M. Yamaguchi, Y.-T. Chen, E. Stockert, et al.
NY-ESO-1 Expression and Immunogenicity in Malignant and Benign Breast Tumors
Cancer Res., March 15, 2004; 64(6): 2199 - 2204.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
H. Gyobu, T. Tsuji, Y. Suzuki, T. Ohkuri, K. Chamoto, M. Kuroki, H. Miyoshi, Y. Kawarada, H. Katoh, T. Takeshima, et al.
Generation and Targeting of Human Tumor-Specific Tc1 and Th1 Cells Transduced with a Lentivirus Containing a Chimeric Immunoglobulin T-Cell Receptor
Cancer Res., February 15, 2004; 64(4): 1490 - 1495.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. Teramoto, K. Kontani, Y. Ozaki, S. Sawai, N. Tezuka, T. Nagata, S. Fujino, Y. Itoh, O. Taguchi, Y. Koide, et al.
Deoxyribonucleic Acid (DNA) Encoding a Pan-Major Histocompatibility Complex Class II Peptide Analogue Augmented Antigen-specific Cellular Immunity and Suppressive Effects on Tumor Growth Elicited by DNA Vaccine Immunotherapy
Cancer Res., November 15, 2003; 63(22): 7920 - 7925.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. Nagorsen, C. Scheibenbogen, F. M. Marincola, A. Letsch, and U. Keilholz
Natural T Cell Immunity against Cancer
Clin. Cancer Res., October 1, 2003; 9(12): 4296 - 4303.
[Abstract] [Full Text] [PDF]

Home page
 Int ImmunolHome page
M. Sato, K. Chamoto, and T. Nishimura
A novel tumor-vaccine cell therapy using bone marrow-derived dendritic cell type 1 and antigen-specific Th1 cells
Int. Immunol., July 1, 2003; 15(7): 837 - 843.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
G. Parmiani, L. Pilla, C. Castelli, and L. Rivoltini
Vaccination of patients with solid tumours
Ann. Onc., June 1, 2003; 14(6): 817 - 824.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Rosato, S. D. Santa, A. Zoso, S. Giacomelli, G. Milan, B. Macino, V. Tosello, P. Dellabona, P.-L. Lollini, C. De Giovanni, et al.
The Cytotoxic T-Lymphocyte Response against a Poorly Immunogenic Mammary Adenocarcinoma Is Focused on a Single Immunodominant Class I Epitope Derived from the gp70 Env Product of an Endogenous Retrovirus
Cancer Res., May 1, 2003; 63(9): 2158 - 2163.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. W. Smith II, E. B. Walker, B. A. Fox, D. Haley, K. P. Wisner, T. Doran, B. Fisher, L. Justice, W. Wood, J. Vetto, et al.
Adjuvant Immunization of HLA-A2-Positive Melanoma Patients With a Modified gp100 Peptide Induces Peptide-Specific CD8+ T-Cell Responses
J. Clin. Oncol., April 15, 2003; 21(8): 1562 - 1573.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. H. Butterfield, A. Ribas, V. B. Dissette, S. N. Amarnani, H. T. Vu, D. Oseguera, H.-J. Wang, R. M. Elashoff, W. H. McBride, B. Mukherji, et al.
Determinant Spreading Associated with Clinical Response in Dendritic Cell-based Immunotherapy for Malignant Melanoma
Clin. Cancer Res., March 1, 2003; 9(3): 998 - 1008.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
N. Meidenbauer, J. Marienhagen, M. Laumer, S. Vogl, J. Heymann, R. Andreesen, and A. Mackensen
Survival and Tumor Localization of Adoptively Transferred Melan-A-Specific T Cells in Melanoma Patients
J. Immunol., February 15, 2003; 170(4): 2161 - 2169.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
I. D. Davis, M. Jefford, P. Parente, and J. Cebon
Rational approaches to human cancer immunotherapy
J. Leukoc. Biol., January 1, 2003; 73(1): 3 - 29.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
L.-X. Wang, B.-G. Chen, and G. E. Plautz
Adoptive Immunotherapy of Advanced Tumors with CD62 L-Selectinlow Tumor-Sensitized T Lymphocytes Following Ex Vivo Hyperexpansion
J. Immunol., September 15, 2002; 169(6): 3314 - 3320.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
H.-M. Hu, C. H. Poehlein, W. J. Urba, and B. A. Fox
Development of Antitumor Immune Responses in Reconstituted Lymphopenic Hosts
Cancer Res., July 15, 2002; 62(14): 3914 - 3919.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
G. Parmiani, C. Castelli, P. Dalerba, R. Mortarini, L. Rivoltini, F. M. Marincola, and A. Anichini
Cancer Immunotherapy With Peptide-Based Vaccines: What Have We Achieved? Where Are We Going?
J Natl Cancer Inst, June 5, 2002; 94(11): 805 - 818.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
V. Monsurro, D. Nagorsen, E. Wang, M. Provenzano, M. E. Dudley, S. A. Rosenberg, and F. M. Marincola
Functional Heterogeneity of Vaccine-Induced CD8+ T Cells
J. Immunol., June 1, 2002; 168(11): 5933 - 5942.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. G. Schaed, V. M. Klimek, K. S. Panageas, C. M. Musselli, L. Butterworth, W.-J. Hwu, P. O. Livingston, L. Williams, J. J. Lewis, A. N. Houghton, et al.
T-Cell Responses against Tyrosinase 368-376(370D) Peptide in HLA*A0201+ Melanoma Patients: Randomized Trial Comparing Incomplete Freund's Adjuvant, Granulocyte Macrophage Colony-stimulating Factor, and QS-21 as Immunological Adjuvants
Clin. Cancer Res., May 1, 2002; 8(5): 967 - 972.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
D. Valmori, V. Dutoit, V. Schnuriger, A.-L. Quiquerez, M. J. Pittet, P. Guillaume, V. Rubio-Godoy, P. R. Walker, D. Rimoldi, D. Lienard, et al.
Vaccination with a Melan-A Peptide Selects an Oligoclonal T Cell Population with Increased Functional Avidity and Tumor Reactivity
J. Immunol., April 15, 2002; 168(8): 4231 - 4240.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
A. Perez-Diez, P. J. Spiess, N. P. Restifo, P. Matzinger, and F. M. Marincola
Intensity of the Vaccine-Elicited Immune Response Determines Tumor Clearance
J. Immunol., January 1, 2002; 168(1): 338 - 347.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. D. Geiger, R. J. Hutchinson, L. F. Hohenkirk, E. A. McKenna, G. A. Yanik, J. E. Levine, A. E. Chang, T. M. Braun, and J. J. Mule
Vaccination Of Pediatric Solid Tumor Patients with Tumor Lysate-pulsed Dendritic Cells Can Expand Specific T Cells and Mediate Tumor Regression
Cancer Res., December 1, 2001; 61(23): 8513 - 8519.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
J. Kjaergaard, L. Peng, P. A. Cohen, J. A. Drazba, A. D. Weinberg, and S. Shu
Augmentation Versus Inhibition: Effects of Conjunctional OX-40 Receptor Monoclonal Antibody and IL-2 Treatment on Adoptive Immunotherapy of Advanced Tumor
J. Immunol., December 1, 2001; 167(11): 6669 - 6677.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C.-L. Tso, A. Zisman, A. Pantuck, R. Calilliw, J. M. Hernandez, S. Paik, D. Nguyen, B. Gitlitz, P. I. Shintaku, J. de Kernion, et al.
Induction of G250-targeted and T-Cell-mediated Antitumor Activity against Renal Cell Carcinoma Using a Chimeric Fusion Protein Consisting of G250 and Granulocyte/Monocyte-Colony Stimulating Factor
Cancer Res., November 1, 2001; 61(21): 7925 - 7933.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. Lee, F. Wang, J. Kuniyoshi, V. Rubio, T. Stuges, S. Groshen, C. Gee, R. Lau, G. Jeffery, K. Margolin, et al.
Effects of Interleukin-12 on the Immune Response to a Multipeptide Vaccine for Resected Metastatic Melanoma
J. Clin. Oncol., September 15, 2001; 19(18): 3836 - 3847.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
J. T. Kurnick, T. Ramirez-Montagut, L. A. Boyle, D. M. Andrews, F. Pandolfi, P. J. Durda, D. Butera, I. S. Dunn, E. M. Benson, S. J. P. Gobin, et al.
A Novel Autocrine Pathway of Tumor Escape from Immune Recognition: Melanoma Cell Lines Produce a Soluble Protein That Diminishes Expression of the Gene Encoding the Melanocyte Lineage Melan-A/MART-1 Antigen Through Down-Modulation of Its Promoter
J. Immunol., August 1, 2001; 167(3): 1204 - 1211.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. Weijzen, S. C. Meredith, M. P. Velders, A. G. Elmishad, H. Schreiber, and W. M. Kast
Pharmacokinetic Differences Between a T Cell-Tolerizing and a T Cell-Activating Peptide
J. Immunol., June 15, 2001; 166(12): 7151 - 7157.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. J. Pittet, A. Zippelius, D. E. Speiser, M. Assenmacher, P. Guillaume, D. Valmori, D. Lienard, F. Lejeune, J.-C. Cerottini, and P. Romero
Ex Vivo IFN-{{gamma}} Secretion by Circulating CD8 T Lymphocytes: Implications of a Novel Approach for T Cell Monitoring in Infectious and Malignant Diseases
J. Immunol., June 15, 2001; 166(12): 7634 - 7640.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. W. Ju, Q. Tao, G. Lou, M. Bai, L. He, Y. Yang, and X. Cao
Interleukin 18 Transfection Enhances Antitumor Immunity Induced by Dendritic Cell-Tumor Cell Conjugates
Cancer Res., May 1, 2001; 61(9): 3735 - 3740.
[Abstract] [Full Text]

Home page
 Clin. Cancer Res.Home page
T. M. Clay, A. C. Hobeika, P. J. Mosca, H. K. Lyerly, and M. A. Morse
Assays for Monitoring Cellular Immune Responses to Active Immunotherapy of Cancer
Clin. Cancer Res., May 1, 2001; 7(5): 1127 - 1135.
[Abstract] [Full Text]

Home page
 J. Immunol.Home page
V. Monsurro, M.-B. Nielsen, A. Perez-Diez, M. E. Dudley, E. Wang, S. A. Rosenberg, and F. M. Marincola
Kinetics of TCR Use in Response to Repeated Epitope-Specific Immunization
J. Immunol., May 1, 2001; 166(9): 5817 - 5825.
[Abstract] [Full Text] [PDF]

Home page
 Arch Otolaryngol Head Neck SurgHome page
W. C. To, B. G. Wood, J. C. Krauss, M. Strome, R. M. Esclamado, P. Lavertu, D. Dasko, J. A. Kim, G. E. Plautz, B. E. Leff, et al.
Systemic Adoptive T-Cell Immunotherapy in Recurrent and Metastatic Carcinoma of the Head and Neck: A Phase 1 Study
Arch Otolaryngol Head Neck Surg, October 1, 2000; 126(10): 1225 - 1231.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
U. S. Kammula, F. M. Marincola, and S. A. Rosenberg
Real-Time Quantitative Polymerase Chain Reaction Assessment of Immune Reactivity in Melanoma Patients After Tumor Peptide Vaccination
J Natl Cancer Inst, August 16, 2000; 92(16): 1336 - 1344.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M.-B. Nielsen, V. Monsurro, S. A. Migueles, E. Wang, A. Perez-Diez, K.-H. Lee, U. Kammula, S. A. Rosenberg, and F. M. Marincola
Status of Activation of Circulating Vaccine-Elicited CD8+ T Cells
J. Immunol., August 15, 2000; 165(4): 2287 - 2296.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
U. S. Kammula, K.-H. Lee, A. I Riker, E. Wang, G. A. Ohnmacht, S. A. Rosenberg, and F. M. Marincola
Functional Analysis of Antigen-Specific T Lymphocytes by Serial Measurement of Gene Expression in Peripheral Blood Mononuclear Cells and Tumor Specimens
J. Immunol., December 15, 1999; 163(12): 6867 - 6875.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1999 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1999 by The American Association of Immunologists, Inc. All rights reserved.